Clover Biopharmaceuticals Ltd.
HHKEX:21971.17
HKD
-0.17
(-12.69%)
Clover Biopharmaceuticals Ltd.
HKEX:2197
(Hong Kong Exchange)
Recent
price
1.17
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- Clover Biopharmaceuticals, Ltd. (2197.HK) Clover Biopharmaceuticals, Ltd. engages in the research, development, manufacture, and commercialization of vaccines and biotherapeutics primarily targeting infectious diseases, cancer, and autoimmune conditions; its core products and pipeline include the SCB-2019 (CpG 1018/Alum) COVID-19 vaccine, AdimFlu-S (QIS) quadrivalent split inactivated influenza vaccine approved and launched in Mainland China, SCB-1019 protein-based RSV vaccine platform with bivalent candidates advancing in U.S. and global trials, SCB-219M thrombopoietin receptor agonist for chemotherapy-induced thrombocytopenia, SCB-313 oncology therapeutic for malignant ascites, pleural effusions, and peritoneal carcinomatosis, SCB-2023B COVID-19 therapeutic, SCB-1001 rabies vaccine, and novel respiratory combination vaccines such as RSV-hMPV-PIV3; the company leverages its proprietary Trimer-Tag technology platform for protein-based vaccines and maintains in-house GMP biomanufacturing capabilities. Founded in 2007 and headquartered in Shanghai, People's Republic of China, with additional facilities in Chengdu, Huzhou, Beijing, Hong Kong, and Boston, United States, Clover Biopharmaceuticals operates principally in Mainland China and pursues international markets through strategic partnerships including CEPI for COVID-19 vaccine development via its Australian subsidiary and global alliances for respiratory vaccines; it targets populations worldwide with a focus on vaccine-preventable diseases and equitable access. Recent developments encompass the October 2025 appointment of Nicholas Jackson, Ph.D., as President of Global R&D and Alliances to bolster innovation and partnerships; positive Phase I data in October 2025 for RSV-hMPV-PIV3 combination vaccines and RSV re-vaccination in older adults; initiation of a Phase I trial in June 2025 for RSV plus hMPV with or without PIV3 candidates; U.S. IND clearance and revaccination study start in March 2025 for SCB-1019; termination of cooperation with Adimmune in June 2025; and prior expansions such as the 2023 quadrivalent influenza vaccine launch and sales network growth in China.